Aquestive Therapeutics (NASDAQ:AQST) Releases Earnings Results, Misses Expectations By $0.08 EPS

Key Points

• Aquestive reported a quarterly EPS loss of $0.18, missing the $0.10-loss consensus by $0.08, while revenue of $13.82 million exceeded estimates of $11.42 million.
• Shares rose 2.8% to $4.41 after the results. Positive human-factors and pharmacokinetic data for Anaphylm strengthened the product’s regulatory and commercial outlook.
• The company’s fiscal 2026 revenue guidance of $46 million to $50 million fell below the $50.8 million analyst consensus at the midpoint, although analysts retain a “Buy” consensus with an average price target of $8.50.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.08), FiscalAI reports. The firm had revenue of $13.82 million for the quarter, compared to the consensus estimate of $11.42 million.

Aquestive Therapeutics Stock Up 2.8%

NASDAQ:AQST traded up $0.12 during trading hours on Tuesday, reaching $4.41. The company had a trading volume of 6,411,656 shares, compared to its average volume of 3,020,570. The firm has a market cap of $553.32 million, a price-to-earnings ratio of -7.23 and a beta of 1.49. The business's 50-day simple moving average is $4.12 and its two-hundred day simple moving average is $4.06. Aquestive Therapeutics has a twelve month low of $2.93 and a twelve month high of $7.55.

Aquestive Therapeutics News Roundup

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: Aquestive reported positive topline human-factors and pharmacokinetic study results for Anaphylm™ (dibutepinephrine) sublingual film. The findings indicated improvements in how users handled and administered the potential anaphylaxis treatment, supporting the product’s usability and regulatory prospects. Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm
• Positive Sentiment: The encouraging Anaphylm study news prompted a sharp move in the stock in the prior session, highlighting the candidate’s importance to Aquestive’s valuation. If development and regulatory milestones remain positive, Anaphylm could provide a significant future commercial opportunity. Aquestive Therapeutics shares jump after encouraging Anaphylm study results
• Neutral Sentiment: Aquestive released second-quarter 2026 financial results and a strategic business update. The announcement gives investors additional information on operating performance and Anaphylm development, but the supplied report does not include enough detail to assess the quarter’s results independently. Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Negative Sentiment: Aquestive’s updated fiscal 2026 revenue guidance of $46.0 million to $50.0 million is below the $50.8 million analyst consensus at the midpoint. The reduced outlook may weigh on sentiment by signaling slower-than-expected near-term revenue growth, although the positive Anaphylm data partially offsets the concern.

Insider Activity

In related news, CEO Daniel Barber sold 8,257 shares of the company's stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $4.29, for a total transaction of $35,422.53. Following the transaction, the chief executive officer directly owned 660,574 shares of the company's stock, valued at approximately $2,833,862.46. This represents a 1.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julie Krop sold 25,000 shares of the business's stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $5.02, for a total value of $125,500.00. Following the sale, the director owned 25,000 shares of the company's stock, valued at approximately $125,500. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.81% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in AQST. NewEdge Advisors LLC bought a new stake in Aquestive Therapeutics during the 3rd quarter worth approximately $28,000. BNP Paribas Financial Markets lifted its stake in Aquestive Therapeutics by 78.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company's stock valued at $31,000 after acquiring an additional 4,134 shares in the last quarter. Modern Wealth Management LLC purchased a new position in Aquestive Therapeutics during the 2nd quarter worth $33,000. Kestra Private Wealth Services LLC purchased a new stake in shares of Aquestive Therapeutics in the third quarter valued at about $60,000. Finally, Abel Hall LLC bought a new position in shares of Aquestive Therapeutics during the 4th quarter worth approximately $74,000. Institutional investors and hedge funds own 32.45% of the company's stock.

Analyst Ratings Changes

A number of brokerages have issued reports on AQST. Wall Street Zen upgraded shares of Aquestive Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, May 16th. Weiss Ratings reissued a "sell (d-)" rating on shares of Aquestive Therapeutics in a research report on Friday, July 17th. Finally, Oppenheimer initiated coverage on Aquestive Therapeutics in a report on Friday, April 24th. They issued an "outperform" rating and a $8.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $8.50.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company's lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source